- WKN: 609500
- ISIN: DE0006095003
- Land: Deutschland
Nachricht vom 05.10.2021 | 07:34
ENCAVIS AG: SCOPE Ratings affirms its investment grade issuer rating BBB- with stable outlook on Encavis AG
DGAP-News: ENCAVIS AG
/ Key word(s): Rating/Financing
SCOPE Ratings affirms its investment grade issuer rating BBB- with stable outlook on Encavis AG
Hamburg, October 5th, 2021 - SDAX-listed solar park and wind farm operator Encavis AG (Prime Standard, ISIN: DE0006095003, Ticker symbol: ECV) has been rated again by SCOPE Ratings (SCOPE) in an updated analysis affirming the investment grade issuer rating (BBB-). The outlook for the rating is Stable. The affirmation reflects SCOPE's view on Encavis' unchanged largely protected business model paired with continuously improving diversification and gradually improving credit metrics.
SCOPE has affirmed its BBB-/Stable issuer rating on Encavis AG and its financing subsidiary Encavis Finance BV. Concurrently, SCOPE affirmed the long-term ratings for senior unsecured debt at BBB-, and BB for subordinated (hybrid) debt and for short-term debt at S-2.
Encavis BBB- rating primarily reflects the Company's largely protected position as an independent power producer with the operation of a generation portfolio that comprises about 3 gigawatts (GW) in 290 renewable energy power plants (wind and solar) across Western Europe (ESG: credit-positive environmental risk factor). SCOPE regards the business model as widely protected as the vast majority of generation assets benefit from prioritised feed-in of generated electricity under availability-based remuneration schemes. Merchant risk for unregulated power plants is widely hedged through long-term power purchase agreements with creditworthy counterparties. Despite some regulatory risk such as recently evidenced through retroactive tariff cuts for part of Encavis solar assets in France, the Company's granular power generation portfolio ensures robust cash flow generation. While weather effects entail some cash flow volatility, such effects are expected to increasingly be softened by the ongoing portfolio ramp-up paired with an increasing granularity of power plant sites, limiting the incremental effects from single generation sites due to adverse weather or tariff/price adjustments. As such, SCOPE believes that Encavis will be able to retain strong margin, e.g. an EBITDA margin of above 70%, and solid cash flow conversion.
While the portfolio ramp-up is expected to be widely backed by the Company's internal funding power through operating cash flow, the closure of a new EUR 125m ESG-linked multi-year revolving credit facility is expected to accelerate expansion along the ">> Fast Forward 2025" growth strategy which targets to grow the owned generation portfolio to 3.4 GW by 2025 (compared to around 1.8 GW as of June 2021). Such enlarged financial shooting power shall enable the Company to execute on opportunistic bolt-on acquisitions of up-and-running renewable energy power plants as well as the investment in ready-to-built power plants from the >3 GW project pipeline of Encavis numerous strategic developing partners.
SCOPE's updated forecasts for 2021E-23E signal increased headroom for the Company's EBITDA against the agency's negative rating-change driver. EBITDA would need to come in 35-55% lower than forecasted before it would reach an EBITDA interest cover of 2.75x, which is the defined trigger for a ratings pressure.
Credit metrics are expected to remain robust in light of Encavis' financial policy that SCOPE views as supportive to maintain the Company's financial risk profile along the acquisitive growth strategy. SCOPE is convinced that the Group's expansion will be balanced against maintaining the financial risk profile's quality. This is evidenced by the Company's funding measures such as the usage of equity-like financing instruments, the offering of scrip dividends, the wide use of financial covenants and cash reserves at project level as well as moderate dividend growth and a minimum equity ratio of 24%.
The rating Outlook remains Stable and incorporates SCOPE's expectation that EBITDA interest coverage will trend towards 4.0x over the next few years. SCOPE also believes the Company will continue to acquire renewable energy power plants and continue to increase dividends, leaving free and discretionary cash flows at around breakeven.
A positive rating action could be warranted if Encavis strengthened EBITDA interest coverage to above 4.0x on a sustained basis paired with further improvements in the granularity of the power generation portfolio.
"The renewed affirmation of the investment grade rating BBB- awarded by the European rating agency SCOPE confirms our consistent financing policy pursued since 2016 with a focus on stable long-term balance sheet ratios", Dr Christoph Husmann, CFO of Encavis AG, welcomed the repeated rating affirmation. "Encavis' excellent credit metrics mirror the very good financial performance of the Group and offers at the same time an increasing range of future financing options to significantly reduced financing costs", Dr Husmann added.
To see the updated issuer report, as well as the rating history including SCOPE's initial public rating on Encavis AG and its debt-issuing subsidiary Encavis Finance BV on March 18, 2019, please click:
Encavis is a signatory of the UN Global Compact as well as of the UN PRI network. Encavis AG's environmental, social and governance performance has been awarded by two of the world's leading ESG rating agencies. MSCI ESG Ratings awarded the corporate ESG performance with "AA" and ISS ESG with their "Prime" label.
|Große Elbstraße 59|
|Phone:||+49 4037 85 62 -0|
|Fax:||+49 4037 85 62 -129|
|Listed:||Regulated Market in Frankfurt (Prime Standard), Hamburg; Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1238216|
|End of News||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
02. Dezember 08:12 Infineon-Aktie: Apple, Omikron und Co belasten - das ist zu tun!
02. Dezember 08:24 Heidelberger Druck: Das ist der wichtigste Kurstreiber
02. Dezember 08:25 Salesforce: Der Zahlen-Schock sitzt tief
02. Dezember 08:28 Volkswagen: Neuer Kurstreiber für die Aktie?!
02. Dezember 08:30 Zalando: Das macht jetzt Hoffnung
News im Fokus
Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025
01. Dezember 2021, 15:38
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: Bio-Gate AG (von GBC AG): Kaufen
02. Dezember 2021